Ausgabe 3/2022
Inhalt (19 Artikel)
- editorial
CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far
Hildegard Greinix
- editorial
Neoadjuvant treatment for solid tumors—the earlier, the better
Rupert Bartsch, Wolfgang Hilbe
- short review
Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management
Emine Kaynak, Johannes Clausen
- short review
CAR T cells in multiple myeloma: Where we stand and where we might be going
Niklas Zojer, Martin Schreder, Heinz Ludwig
- Open Access
- review
Applicability of ESMO-MCBS and ESCAT for molecular tumor boards
Ladislaia Wolff, Barbara Kiesewetter
- Open Access
- short review
Molecular profiling leading to personalized treatment in breast cancer
Eva Valentina Klocker, Marija Balic, Günther Steger
- Open Access
- short review
Molecular profiling in lung cancer
Laurenz Nagl, Georg Pall, Dominik Wolf, Andreas Pircher, Lena Horvath
- Open Access
- short review
Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better
Angelika Terbuch, Gudrun Absenger
- short review
Neoadjuvant treatment of pancreatic ductal adenocarcinoma
Katharina Kosma, Sabine Thalhammer, Thomas Gruenberger
- short review
Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer
Renate Pusch
- case report
Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review
Federico Ghidinelli, Luigi Filippini, Paola Porsio, Federico Canzi, Rino Balzano, Elisa Flocchini, Anna Bianchi
- comment
Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities
Andreas Pircher, Roberto N. Miranda
- short review
Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021
Patrick Reimann, Thomas Winder
- case report
Multiple myeloma with central nervous system relapse: a case report
Petra Marics, Wolfgang Pokieser, Nikolaus Neubauer, Georg Slavka, Wolfgang Hilbe, Martin Schreder
- original report
Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment
Sara Dâmaso, Rita Paiva, Inês Pinho, Miguel Esperança-Martins, Raquel Lopes Brás, Cecília Melo Alvim, António Quintela, Ana Lúcia Costa, Luís Costa
- Open Access
- Publisher Correction
Publisher Correction: Brain metastases: new systemic treatment approaches
Ariane Steindl, Anna Sophie Berghoff
